

Memantine Hydrochloride (Namenda) XR Capsules Shortage

February 5, 2015

There is a shortage of memantine hydrochloride (Namenda) XR capsules manufactured by Forest Laboratories, Inc.

Presentation	Estimated Shortage Duration	Related Information
Namenda XR 14 mg 10 x 10 Unit Dose: (NDC 0456-3414-63)	Product currently unavailable; estimated duration 6 months	Manufacturing delay based upon commercial stability data and the discontinuation of blister packaging.
Namenda XR 28 mg 10 x 10 Unit Dose (NDC 0456-3428-63)	Product currently unavailable; estimated duration 6 months	Manufacturing delay based upon commercial stability data and the discontinuation of blister packaging.
Namenda XR Titration Pack: Contains 28 capsules (7 x 7 mg, 7 x 14 mg, 7 x 21 mg, 7 x 28 mg) (NDC 0456-3400-29)	Product currently unavailable; estimated duration 6 months	Manufacturing delay based upon commercial stability data and the discontinuation of blister packaging.

Healthcare professionals and patients are encouraged to report any adverse events or side effects related to the use of this product and/or quality problems to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

- ✓ Complete and submit the report online: www.fda.gov/MedWatch/report.htm
- ✓ Complete and return a form by mail (address on the pre-addressed form) or fax (1-800-FDA-0178).
[Call 1-800-332-1088 to request a reporting form or download a form at
<http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm>.]

Source:

http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Memantine+Hydrochloride+%28Namenda%29+XR+Capsules&source=govdelivery&st=c&tab=tabs-4&utm_medium=email&utm_source=govdelivery